Amy Alford

Mrs. Alford has been leading Senti’s R&D and clinical operations since 2022. She brings over 20 years of clinical operations experience, including departmental build outs and trial progression from First in Human/Phase I to registration. Prior to joining Senti, Mrs. Alford held various clinical roles at Kronos Bio, Peloton Therapeutics (acquired by Merck), and Reata Pharmaceuticals. She was also a clinical research consultant advising a number of companies on clinical development, strategy, and operations. Mrs. Alford was part of the clinical teams for several FDA-approved products, including WELIREG® for the treatment of von Hippel-Lindau (VHL)-associated renal cell carcinoma.

Mrs. Alford earned a master’s degree in Clinical, Counseling and Applied Psychology from Northwestern University, and a bachelor’s degree in Biology & Psychology from Rhodes College.